|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.
|
22235286 |
2012 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF kinase inhibitors have dramatically affected treatment of BRAF(V600E) (/) (K)-driven metastatic melanoma.
|
25948295 |
2015 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Vemurafenib is an inhibitor of the BRAF V600E mutation which is associated with tumor responses in patients with metastatic melanoma.
|
24815010 |
2017 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.
|
22663011 |
2012 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Assessment of BRAF p.V600E mutational status has become necessary for treatment of patients with metastatic melanoma.
|
23651150 |
2014 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
|
29076950 |
2017 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study investigated the sensitivity and specificity of immunohistochemical (IHC) analysis using an anti-BRAF antibody to detect the presence of the BRAF V600E mutation in patients with metastatic melanoma.
|
23026937 |
2013 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We describe peripheral blood smear, bone marrow morphology, histopathology, immunohistochemistry, including BRAF V600E, and molecular testing results of patients with metastatic melanoma to the bone marrow.
|
31112348 |
2019 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma-Association with Clinical Outcome and Tumor Phenotypes.
|
31835364 |
2019 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The development of targeted inhibitors, like vemurafenib, has greatly improved the clinical outcome of BRAF(V600E) metastatic melanoma.
|
26105199 |
2015 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation.
|
22037033 |
2011 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dabrafenib is an inhibitor of BRAF V600E used for treating metastatic melanoma but a majority of patients experience adverse effects.
|
28429064 |
2017 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of the BRAF V600E mutation is required for use of the BRAF inhibitor, vemurafenib, in patients with metastatic melanoma.
|
23994118 |
2013 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.
|
24178368 |
2014 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.
|
20818844 |
2010 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
IHC-measured BRAF(V600E) protein expression displays complete intertumoral homogeneity, minimal intertumoral intensity heterogeneity, and no intratumoral heterogeneity in metastatic melanoma patients in various stages of disease progression.
|
24335665 |
2014 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We describe a 50-year-old Hispanic woman with BRAF V600E mutant metastatic melanoma who was treated with surgery, radiation therapy, interleukin-2, and was enrolled on a BRAFi (dabrafenib) trial.
|
25839886 |
2015 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The phase III study of dabrafenib in BRAF(V600E) metastatic melanoma reported rapid tumor regression in most patients and a 59% objective RECIST response rate.
|
24583796 |
2014 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations.
|
25399551 |
2015 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Vemurafenib is a new-targeted therapy approved for the treatment of patients with V600E BRAF-mutant metastatic melanoma.
|
23528218 |
2013 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Intrinsic and acquired resistance of metastatic melanoma to (V600E/K)BRAF and/or MEK inhibitors, which is often caused by activation of the PI3K/AKT survival pathway, represents a major clinical challenge.
|
26790143 |
2016 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Trametinib, a mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor, has demonstrated great promise in treating metastatic melanoma associated with BRAF V600E and V600K mutations; however, it also is highly associated with cutaneous adverse events (AEs).
|
30489553 |
2018 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The loss of the (V599E)BRAF genotype during progression from primary to metastatic melanoma in patients with (V599E)BRaf specific T-cell responses suggests an active immune selection of nonmutated melanoma clones by the tumor-bearing host.
|
15289355 |
2004 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma.
|
27336602 |
2016 |
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
V600E) and the subsequent development of specific BRAF inhibitors have greatly improved the treatment of metastatic melanoma.
|
23413975 |
2013 |